46
Participants
Start Date
March 16, 2018
Primary Completion Date
October 10, 2024
Study Completion Date
July 16, 2026
Cyclophosphamide
Given IV
Doxorubicin Hydrochloride
Given IV
Etoposide
Given IV
Filgrastim
Given SC
Ibrutinib
Given PO
Laboratory Biomarker Analysis
Correlative studies
Pegfilgrastim
Given SC
Pharmacological Study
Correlative studies
Prednisone
Given PO
Rituximab
Given IV
Vincristine Sulfate
Given IV
Mount Sinai Hospital, New York
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center - Moses Campus, The Bronx
Memorial Sloan Kettering Nassau, Uniondale
Pennsylvania Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Memorial Hospital West, Pembroke Pines
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Ohio State University Comprehensive Cancer Center, Columbus
John H Stroger Jr Hospital of Cook County, Chicago
University of Illinois College of Medicine - Chicago, Chicago
Siteman Cancer Center at Washington University, St Louis
Washington University School of Medicine, St Louis
UC San Diego Moores Cancer Center, La Jolla
UCSF Medical Center-Parnassus, San Francisco
Virginia Mason Medical Center, Seattle
Boston Medical Center, Boston
National Cancer Institute (NCI)
NIH